

# Ayesha N Shajahan-Haq

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1252491/publications.pdf>

Version: 2024-02-01

59  
papers

7,090  
citations

249298

26  
h-index

263392

45  
g-index

61  
all docs

61  
docs citations

61  
times ranked

19141  
citing authors

#	ARTICLE	IF	CITATIONS
1	Caveolin-1 controls mitochondrial damage and ROS production by regulating fission - fusion dynamics and mitophagy. <i>Redox Biology</i> , 2022, 52, 102304.	3.9	32
2	Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. <i>Cancer</i> , 2021, 127, 3622-3630.	2.0	8
3	Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 681530.	1.3	15
4	Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12292.	1.8	31
5	Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition. <i>Journal of the Royal Society Interface</i> , 2020, 17, 20200339.	1.5	12
6	Inhibition of DNA Repair Pathways and Induction of ROS Are Potential Mechanisms of Action of the Small Molecule Inhibitor BOLD-100 in Breast Cancer. <i>Cancers</i> , 2020, 12, 2647.	1.7	25
7	Abstract P3-09-14: Regulation of gene expression and DNA methylation with cytotoxic T lymphocytes evaluation in subtypes of breast cancers. , 2020, , .		0
8	Abstract P1-19-20: Safety of palbociclib in African American women with hormone receptor positive HER2 negative advanced breast cancer and benign ethnic neutropenia: PALINA study. , 2020, , .		0
9	Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 686.	1.3	41
10	Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 595-603.	1.1	106
11	Abstract 674: Predicting cellular response to therapy in breast cancer using mathematical modeling. , 2019, , .		0
12	Dielectrophoretic properties distinguish responses to estrogen and fulvestrant in breast cancer cells. <i>Sensors and Actuators B: Chemical</i> , 2018, 277, 186-194.	4.0	3
13	PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. <i>Contemporary Clinical Trials Communications</i> , 2018, 10, 190-192.	0.5	7
14	Promoting Scientistâ€™ Advocate Collaborations in Cancer Research: Why and How. <i>Cancer Research</i> , 2018, 78, 5723-5728.	0.4	27
15	CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities. , 2018, 191, 65-73.		50
16	SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1038-1038.	0.8	7
17	Abstract 2862: Inhibition of DNA repair pathways in breast cancer is a potential mechanism of action of IT-139. , 2018, , .		0
18	Breast cancer cell obatoclax response characterization using passivatedâ€™electrode insulatorâ€™based dielectrophoresis. <i>Electrophoresis</i> , 2017, 38, 1988-1995.	1.3	23

#	ARTICLE	IF	CITATIONS
19	PSSV: a novel pattern-based probabilistic approach for somatic structural variation identification. <i>Bioinformatics</i> , 2017, 33, 177-183.	1.8	5
20	EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer. <i>Oncotarget</i> , 2017, 8, 96865-96884.	0.8	29
21	MYC-Driven Pathways in Breast Cancer Subtypes. <i>Biomolecules</i> , 2017, 7, 53.	1.8	152
22	Abstract 430: Combination of CB-839 and everolimus is effective in inhibiting growth of endocrine resistant breast cancer in vivo. , 2017, , .		0
23	Systems Approaches to Cancer Biology. <i>Cancer Research</i> , 2016, 76, 6774-6777.	0.4	26
24	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
25	ChIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of ChIP-seq profiles. <i>Nucleic Acids Research</i> , 2016, 44, e65-e65.	6.5	15
26	Abstract 1508: Integration of transcriptomic and metabolomic data reveals a central role for EGR1 in regulating survival and cellular metabolism in endocrine-resistant breast cancer. , 2016, , .		1
27	Caveolin-1 regulates cancer cell metabolism via scavenging Nrf2 and suppressing MnSOD-driven glycolysis. <i>Oncotarget</i> , 2016, 7, 308-322.	0.8	42
28	Dynamic Modeling of the Interaction Between Autophagy and Apoptosis in Mammalian Cells. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 263-272.	1.3	67
29	Application of Metabolomics in Drug Resistant Breast Cancer Research. <i>Metabolites</i> , 2015, 5, 100-118.	1.3	50
30	BMRf-Net: a software tool for identification of protein interaction subnetworks by a bagging Markov random field-based method. <i>Bioinformatics</i> , 2015, 31, 2412-2414.	1.8	30
31	Interferon Regulatory Factor-1 Signaling Regulates the Switch between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate. <i>Cancer Research</i> , 2015, 75, 1046-1055.	0.4	31
32	Integrating Proteotoxic Stress Response Pathways for Induction of Cell Death in Cancer Cells: Molecular Mechanisms and Therapeutic Opportunities. , 2015, , 183-202.		0
33	Abstract 1258: The unfolded protein response may contribute to racial disparity in endocrine responsiveness in breast cancer. , 2015, , .		1
34	Abstract B2-09: A systems biology approach to understanding estrogen responsiveness in breast cancer cells using the MCF7 model. , 2015, , .		0
35	Abstract B1-23: Early growth response (EGR1) is a critical regulator of cellular metabolism and predicts increased responsiveness to antiestrogens in breast cancer. , 2015, , .		0
36	MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. <i>Molecular Cancer</i> , 2014, 13, 239.	7.9	74

#	ARTICLE	IF	CITATIONS
37	Glutamine metabolism and the unfolded protein response in MYC-driven breast cancer. <i>Cancer &amp; Metabolism</i> , 2014, 2, .	2.4	1
38	Abstract 1634: A novel small molecule inhibitor of IRE1alpha reverses endocrine resistance in breast cancer cells. , 2014, , .		0
39	Abstract 679: Glutamine metabolism in MYC-driven antiestrogen resistant breast cancer cells confers metabolic flexibility through the unfolded protein response. , 2014, , .		0
40	Abstract C73: Differences in UPR signaling in ER+ breast cancer between African American and Caucasian women. , 2014, , .		0
41	Modelling the effect of GRP78 on anti-oestrogen sensitivity and resistance in breast cancer. <i>Interface Focus</i> , 2013, 3, 20130012.	1.5	26
42	Nitrosationâ€Dependent Caveolin 1âPhosphorylation, Ubiquitination, and Degradation and its Association with Idiopathic Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 816-830.	0.8	59
43	GX15-070 (Obatoclox) Induces Apoptosis and Inhibits Cathepsin D- and Lâ€Mediated Autophagosomal Lysis in Antiestrogen-Resistant Breast Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 448-459.	1.9	49
44	A novel statistical approach to identify co-regulatory gene modules. , 2013, , .		2
45	Tyrosine-phosphorylated Caveolin-1 (Tyr-14) Increases Sensitivity to Paclitaxel by Inhibiting BCL2 and BCLxL Proteins via c-Jun N-terminal Kinase (JNK). <i>Journal of Biological Chemistry</i> , 2012, 287, 17682-17692.	1.6	58
46	Glucose-Regulated Protein 78 Controls Cross-talk between Apoptosis and Autophagy to Determine Antiestrogen Responsiveness. <i>Cancer Research</i> , 2012, 72, 3337-3349.	0.4	133
47	Endoplasmic Reticulum Stress, the Unfolded Protein Response, Autophagy, and the Integrated Regulation of Breast Cancer Cell Fate. <i>Cancer Research</i> , 2012, 72, 1321-1331.	0.4	183
48	Vitamin E succinate inhibits survivin and induces apoptosis in pancreatic cancer cells. <i>Genes and Nutrition</i> , 2012, 7, 83-89.	1.2	19
49	Autophagy and endocrine resistance in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1283-1294.	1.1	137
50	Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2011, 5, 35-44.	0.3	49
51	The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer. <i>International Journal of Breast Cancer</i> , 2011, 2011, 1-9.	0.6	36
52	BCL2 and CASP8 regulation by NFâ€PB differentially affect mitochondrial function and cell fate in antiestrogenâ€sensitive and â€resistant breast cancer cells. <i>FASEB Journal</i> , 2010, 24, 2040-2055.	0.2	76
53	Co-Inhibition of BCL-W and BCL2 Restores Antiestrogen Sensitivity through BECN1 and Promotes an Autophagy-Associated Necrosis. <i>PLoS ONE</i> , 2010, 5, e8604.	1.1	60
54	Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 114, 8-20.	1.2	73

#	ARTICLE	IF	CITATIONS
55	The role of X-box binding protein-1 in tumorigenicity. Drug News and Perspectives, 2009, 22, 241.	1.9	64
56	Caveolin-1 Tyrosine Phosphorylation Enhances Paclitaxel-mediated Cytotoxicity. Journal of Biological Chemistry, 2007, 282, 5934-5943.	1.6	61
57	Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB Journal, 2007, 21, 4013-4027.	0.2	169
58	Tyrosine phosphorylation dependence of caveolin-1 mediated endocytosis. Journal of Cellular and Molecular Medicine, 2007, 11, 1239-1250.	1.6	96
59	Novel Mechanism of Endothelial Nitric Oxide Synthase Activation Mediated by Caveolin-1 Internalization in Endothelial Cells. Circulation Research, 2006, 99, 870-877.	2.0	122